- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 00:30 | US IPO Weekly Recap: Aktis Oncology leads as first sizable 2026 IPO | 1 | Renaissance Capital | ||
| Fr | Lilly partner Aktis surges on trading debut | 2 | Seeking Alpha | ||
| Fr | Aktis Oncology feiert starkes Börsendebüt mit 50 % Kursplus | 5 | Investing.com Deutsch | ||
| Fr | Aktis Has First Biotech IPO of 2026, Raising $318M to Expand the Reach of Radiopharmaceuticals | 1 | MedCity News | ||
| Fr | Phase 1 solid tumor biotech Aktis Oncology prices IPO at $18, the high end of the range | 2 | Renaissance Capital | ||
| AKTIS ONCOLOGY Aktie jetzt für 0€ handeln | |||||
| Fr | 1st biotech IPO of 2026 sees Aktis bring in $318M via upsized offering | 1 | FierceBiotech | ||
| Fr | Aktis Oncology prices IPO at $18 per share | 2 | Seeking Alpha | ||
| Fr | Aktis Oncology prices upsized US IPO at $18 per share | 2 | Reuters | ||
| Do | Aktis Oncology: Erster US-Börsengang des Jahres - die Hintergründe | 517 | Der Aktionär | Die Wall Street kann sich in Kürze über ein weiteres Biotech-Unternehmen freuen. Der Radiopharma-Spezialist Aktis Oncology strebt an die Nasdaq und will mit dem Listing einen dreistelligen Millionen-Dollar-Betrag... ► Artikel lesen | |
| Mi | Aktis Oncology, Inc. - 8-A12B, Registration of securities | 1 | SEC Filings | ||
| Mi | Aktis Oncology stockt Börsengang um 50 % auf - Eli Lilly bekundet Kaufinteresse über 100 Mio. USD | 10 | Investing.com Deutsch | ||
| Mi | Aktis Oncology increases proposed IPO deal size by 50% to $300 million, adding a $100 million commitment from partner Eli Lilly | 7 | Renaissance Capital | ||
| Mi | Aktis Oncology targets up to $945 million valuation in upsized US IPO | 2 | Reuters | ||
| Di | Aktis Oncology kicks 2026 IPO cycle off with $210m target | 10 | Pharmaceutical Technology | ||
| Mo | Lilly partner Aktis targets up to $840M valuation in U.S. IPO | 8 | Seeking Alpha | ||
| Mo | US IPO Week Ahead: Aktis Oncology set to open 2026 IPO Market | 1 | Renaissance Capital | ||
| Mo | Phase 1 solid tumor biotech Aktis Oncology sets terms for $200 million IPO; expected to trade on Friday 1/9 in first sizable IPO of 2026 | 1 | Renaissance Capital | ||
| Mo | Aktis Oncology aims for $209M windfall from 1st biotech IPO of 2026 | 2 | FierceBiotech | ||
| Mo | Aktis Oncology files much-expanded IPO | 1 | pharmaphorum | ||
| Mo | Aktis Oncology, Inc. - S-1/A, General form for registration of securities | - | SEC Filings |
1 2 Weiter >>
26 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MOONLAKE IMMUNOTHERAPEUTICS | 18,610 | +29,69 % | MoonLake Immunotherapeutics AG: MoonLake Immunotherapeutics Announces Positive Outcome from Type B Meeting with U.S. FDA and Announces Investor Day | MoonLake requested a Type B meeting with the U.S. Food and Drug Administration (FDA) to obtain regulatory clarity and discuss the clinical evidence strategy for submission of a Biologic License Application... ► Artikel lesen | |
| CG ONCOLOGY | 54,30 | +29,49 % | CG Oncology Inc.: CG Oncology Provides Updated Timeline for PIVOT-006 Phase 3 Topline Data in Intermediate-Risk NMIBC | - PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy for intermediate-risk NMIBC now expected in 1H 2026, nearly one year ahead of schedule - First randomized registrational trial... ► Artikel lesen | |
| QIAGEN | 41,230 | -0,15 % | XFRA CAPITAL ADJUSTMENT INFORMATION - 07.01.2026 | Das Instrument SFTU US83404D1090 SOFTBANK GR.UNS.ADR1/2/ON EQUITY wird cum Kapitalmassnahme gehandelt am 07.01.2026 und ex Kapitalmassnahme am 08.01.2026 The instrument SFTU US83404D1090 SOFTBANK GR.UNS.ADR1/2/ON... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 26,245 | +12,74 % | Enliven Therapeutics, Inc.: Enliven Reports Positive Initial Phase 1b Data for ELVN-001 in CML and Outlines 2026 Clinical Milestones | Cumulative major molecular response (MMR) rate of 69% by 24 weeks, with 53% of patients achieving MMR by 24 weeks in ongoing randomized Phase 1b cohorts
ELVN-001... ► Artikel lesen | |
| VENTYX BIOSCIENCES | 13,805 | -0,18 % | Ventyx Biosciences und BioAge Labs: Tenbagger-Rendite im No Brainer Club! | Mit Ventyx Biosciences feiert der No Brainer Club eine waschechte Tenbagger-Empfehlung: Nach Übernahmegerüchten springt die Aktie heute im regulären Handel zunächst um rund 30% nach oben, bevor sie... ► Artikel lesen | |
| MONTE ROSA THERAPEUTICS | 24,250 | -4,19 % | Monte Rosa Therapeutics, Inc.: Monte Rosa Therapeutics Announces Pricing of $300 Million Underwritten Public Offering | BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. ("Monte Rosa") (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines... ► Artikel lesen | |
| ALUMIS | 19,550 | +7,59 % | Alumis raises $345.1 million in upsized public offering | ||
| TRAVERE THERAPEUTICS | 34,580 | -2,87 % | Vifor International AG (CSL Vifor): CSL Vifor and Travere Therapeutics Recognize Updated KDIGO Clinical Practice Guidelines for IgA Nephropathy | FILSPARI® (sparsentan) suggested for IgA Nephropathy patients who are at risk of progressive kidney function loss
ST. GALLEN, Switzerland, and SAN DIEGO, Sept. 26, 2025 /PRNewswire/... ► Artikel lesen | |
| ERASCA | 6,705 | +14,81 % | What's Going With Cancer Biotech Erasca Stock On Thursday? | ||
| AVIDITY BIOSCIENCES | 72,39 | +0,06 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| ARCELLX | 66,31 | +3,11 % | UBS initiates Arcellx stock coverage with Buy rating, $100 price target | ||
| ARS PHARMACEUTICALS | 13,130 | +19,91 % | ARS Pharma (SPRY) Gains China Approval for Neffy, Roth Reiterates Buy Rating | ||
| COGENT BIOSCIENCES | 35,330 | -0,67 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in NonAdvanced Systemic Mastocytosis | WALTHAM, Mass. and BOULDER, Colo., Dec. 30, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined... ► Artikel lesen | |
| TANGO THERAPEUTICS | 11,820 | +6,92 % | Tango Therapeutics Sub, Inc: Tango Therapeutics Announces CEO Transition: Barbara Weber to Retire, Malte Peters Appointed Successor | Founding CEO Barbara Weber, M.D. to become executive chair of the board of directorsMalte Peters, M.D., current board member, appointed President and Chief Executive Officer, effective immediately... ► Artikel lesen | |
| REGENCELL BIOSCIENCE | 46,240 | +11,18 % | Regencell Bioscience is the top performing pharma stock YTD |
AKTIS ONCOLOGY INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 22,460 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu AKTIS ONCOLOGY INC finden Sie auf Wallstreet Online.